POSTN upregulation has been demonstrated for many cancer types, such as non-small cell lung cancer (NSCLC) [24,26], invasive ductal breast cancer (IDC) [27], pancreatic [28], and ovarian cancer [29], and is consequently defined as a tumor-enhancing factor [17]. This evidence concerns the gene POSTN and non-small cell lung carcinoma.